Literature DB >> 27686597

PARP inhibitors and stratified treatment of prostate cancer.

Anita Lavery1, Clare Gilson2, Simon Chowdhury3.   

Abstract

Entities:  

Keywords:  BRCA1/2 mutation; Biomarker; PARP inhibitor; prostate cancer; stratification; targeted therapy

Mesh：

Substances：

Year:  2016        PMID： 27686597     DOI： 10.1080/14737140.2016.1243474

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  4 in total

Review 1.  Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.

Authors:  Johnny R Ramroop; Mark N Stein; Justin M Drake
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

2.  Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

Authors:  Toni Rose Jue; Kyoko Nozue; Ashleigh J Lester; Swapna Joshi; Lisette B W Schroder; Shane P Whittaker; Sheri Nixdorf; Robert W Rapkins; Mustafa Khasraw; Kerrie L McDonald
Journal:  J Transl Med       Date:  2017-03-17       Impact factor: 5.531

Review 3.  Defective DNA repair mechanisms in prostate cancer: impact of olaparib.

Authors:  Francesca De Felice; Vincenzo Tombolini; Francesco Marampon; Angela Musella; Claudia Marchetti
Journal:  Drug Des Devel Ther       Date:  2017-03-01       Impact factor: 4.162

4.  Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.

Authors:  Radivojka Bánová Vulić; Martina Zdurienčíková; Silvia Tyčiaková; Oldřich Benada; Mária Dubrovčáková; Ján Lakota; Ľudovít Škultéty
Journal:  J Cell Mol Med       Date:  2019-03-27       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.